《JAK抑制剂：在炎症性肠病治疗策略中的当前地位》勘误 - Suppr | 超能文献

Corrigendum to 'JAK inhibitors: Current position in treatment strategies for use in inflammatory bowel disease'.

作者信息

Hernandez-Rocha Cristian, Vande Casteele Niels

出版信息

Curr Opin Pharmacol. 2021 Jun;58:68. doi: 10.1016/j.coph.2021.03.009. Epub 2021 Apr 28.

DOI:10.1016/j.coph.2021.03.009

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Corrigendum to 'JAK inhibitors: Current position in treatment strategies for use in inflammatory bowel disease'.《JAK抑制剂：在炎症性肠病治疗策略中的当前地位》勘误

Curr Opin Pharmacol. 2021 Jun;58:68. doi: 10.1016/j.coph.2021.03.009. Epub 2021 Apr 28.

2

JAK inhibition in inflammatory bowel disease.炎症性肠病中的JAK抑制作用。

Expert Rev Clin Immunol. 2017 Jul;13(7):693-703. doi: 10.1080/1744666X.2017.1291342. Epub 2017 Feb 17.

3

Corrigendum to 'ESPEN guideline: Clinical nutrition in inflammatory bowel disease' [Clinical Nutrition 36 (2) (2016) 321-347].《欧洲临床营养和代谢学会（ESPEN）指南：炎症性肠病的临床营养》勘误 [《临床营养》36(2)(2016) 321 - 347]

Clin Nutr. 2019 Jun;38(3):1485. doi: 10.1016/j.clnu.2019.03.004. Epub 2019 Mar 14.

4

JAK Inhibition: The Most Promising Agents in the IBD Pipeline?JAK 抑制剂：炎症性肠病药物研发管线上最有前途的药物？

Curr Pharm Des. 2019;25(1):32-40. doi: 10.2174/1381612825666190405141410.

5

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.JAK/STAT 信号通路在炎症性肠病发病机制中的作用。

Pharmacol Res. 2013 Oct;76:1-8. doi: 10.1016/j.phrs.2013.06.007. Epub 2013 Jul 2.

6

JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?JAK 选择性治疗炎症性肠病：这在临床上有意义吗？

Gut. 2019 Oct;68(10):1893-1899. doi: 10.1136/gutjnl-2019-318448. Epub 2019 Jun 21.

7

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.使用托法替布抑制JAK治疗炎症性肠病：多种炎症细胞因子的汇聚点

Am J Physiol Gastrointest Liver Physiol. 2016 Feb 1;310(3):G155-62. doi: 10.1152/ajpgi.00311.2015. Epub 2015 Nov 25.

8

Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.系统评价与荟萃分析：口服 Janus 激酶抑制剂治疗炎症性肠病的疗效和安全性。

Aliment Pharmacol Ther. 2019 Jul;50(1):5-23. doi: 10.1111/apt.15297. Epub 2019 May 23.

9

Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.溃疡性结肠炎和克罗恩病患者中 JAK/STAT 信号转导的差异调节。

World J Gastroenterol. 2020 Jul 28;26(28):4055-4075. doi: 10.3748/wjg.v26.i28.4055.

10

JAK inhibitors and infections risk: focus on herpes zoster.JAK抑制剂与感染风险：聚焦带状疱疹

Ther Adv Musculoskelet Dis. 2020 Jun 29;12:1759720X20936059. doi: 10.1177/1759720X20936059. eCollection 2020.

引用本文的文献

1

3-oxo-C12:2-HSL, quorum sensing molecule from human intestinal microbiota, inhibits pro-inflammatory pathways in immune cells via bitter taste receptors.3-氧代-C12:2-HSL，来自人类肠道微生物群的群体感应分子，通过苦味受体抑制免疫细胞中的促炎途径。

Sci Rep. 2022 Jun 8;12(1):9440. doi: 10.1038/s41598-022-13451-3.